iX Biopharma secures $52.8m US contract for pain reliever trials

The funding will be allocated for the late-stage development of Wafermine.

Singapore-listed iX Biopharma has secured a $52.8m (US$41m) contract from the US Department of Defense to fund late-stage development of Wafermine, a fast-dissolving sublingual ketamine wafer, according to a press release.

The company said the treatment is intended for situations where conventional pain management is impractical or delayed, including battlefield trauma, emergency response, remote care, and mass-casualty settings.

The programme will support Phase 3 clinical development and a potential Emergency Use Authorisation pathway.

The announcement was followed by a placement agreement with OCBC to raise at least $6m at $0.198 per share from institutional and accredited investors. Strong demand subsequently led to an upsized placement of approximately $15m.

About $13m is earmarked for execution of the US government programme and working capital, whilst $2m is for debt repayment.

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia